Effect of basal insulin and omega 3 fatty acids on cognitive impairment in dysglycaemia: An exploratory analysis of the outcomes reduction with an initial glargine intervention (ORIGIN) trial
Authors' conclusion
In this post hoc exploratory analysis, insulin glargine-mediated normoglycaemia but not omega 3 fatty acids reduced the hazard of substantive cognitive impairment in people with dysglycaemia and additional cardiovascular risk factors.
Study context
- Population
- Participants with dysglycaemia and additional cardiovascular risk factors, 573 sites in 40 countries
- Participants
- 11,682 participants
- Comparison
- Insulin glargine vs standard care; omega 3 fatty acids vs placebo
- Primary endpoint
- Country-standardized substantive cognitive impairment: first baseline-adjusted follow-up mini mental state examination or digit symbol substitution test score ≥1.5 SD below the baseline mean score in the participant's country
- Follow-up
- Median 6.2 years
Methodological detailspost hoc exploratory analysis, factorial
- Post hoc exploratory analysis
- Factorial
Primary result
As reported in the abstract
Country-standardized substantive cognitive impairment
Hazard ratio (95% CI)P value
Insulin glarginevs Standard care
0.91(0.85–0.99)
P = 0.023Omega 3 fatty acidsvs Placebo
0.93(0.86–1.01)
P = 0.074- Developed country-standardized substantive cognitive impairment (overall)
- 2627 of 11 682 (22.5%)
Original publication
Effect of basal insulin and omega 3 fatty acids on cognitive impairment in dysglycaemia: An exploratory analysis of the ORIGIN trial. Diabetes Obes Metab. Published 10 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →